Listed drug producer Renata PLC has completed shipment of the first consignment of Risperidone, a tablet used for the management of psychiatric disorders, to the USA.

The product, marketed as Sperid locally, was manufactured at Renata's Bangladesh facility approved by the US Food and Drug Administration, the company said in a statement today.

The initial shipment includes a total of 12 million tablets across lower dosage strengths of 0.25 mg, 0.5 mg, and 1 mg.

In addition to these strengths, Renata is also in the process of obtaining approval for higher doses of 2 mg, 3 mg, and 4 mg, according to the statement.

"This ensures availability of comprehensive options for patients requiring precision in dosage adjustments which is crucial in the treatment of Schizhophrenia, Bipolar Disorder and irritability associated with Autism," Renata said.

This event marks yet another new addition to the Renata US portfolio, it said.

This time, Renata targets the market for neurological disorders that have a significant disease burden on the population of the USA, the Bangladeshi company said.